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a b s t r a c t
Human glucagon-like peptide-1 (GLP-1) is a physiological gastrointestinal peptide with glucose-dependent
insulinotropic effects which is therefore considered an interesting antidiabetic agent. However, after in
vivo administration, exogenous GLP-1 does not exert its physiological action due to the combination of
rapid proteolytic degradation by ubiquitous dipeptidyldipeptidase IV (DPP IV) enzyme and renal clearance
resulting in an extremely short circulating half-life. In this work we describe the conjugation of GLP-1-(7-
36)-amide derivatives with polyethylene glycol (PEG) by enzymatic site-speciﬁc transglutamination reaction
as an approach to reduce both the proteolysis and the renal clearance rates.
The compound GLP-1-(7-36)-amide-Q23-PEG 20kDa monopegylated on the single glutamine residue natu-
rally present in position 23 maintained the ability to activate the GLP-1 receptor expressed in the rat β-cell
line RIN-m5F with nanomolar potency along with an increased in vitro resistance to DDP IV and a circulating
half-life of about 12h after subcutaneous administration in rats. These properties enabled GLP-(7-36)-amide-
Q23-PEG 20kDa to exert a glucose-stabilizing effect for a period as long as 8h, as demonstrated by a single
subcutaneous injection to diabetic mice concomitantly challenged with an oral glucose load.
The results reported in this work indicate that GLP-(7-36)-amide-Q23-PEG 20kDa could be a lead compound
for the development of long-lasting anti-diabetic agents useful in the treatment of type 2 diabetes affected
patients.
c© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Human glucagon-like peptide-1 (GLP-1), a prototypical incretin
hormone that potentiates insulin secretion under elevated glycemic
conditions, is a posttranslational cleavage product of proglucagon
which is secreted from enteroendocrine L-cells of the intestine after
food intake. GLP-1 displays a potent blood glucose-lowering effect
through different physiological mechanisms, including the secretion
of endogenous insulin inaglucose-dependentmanner, thedecreaseof
blood glucagon levels and the reduction of gastric emptying by slow-
ing gastric motility [1]. Besides these properties, GLP-1 stimulates
the proliferation and differentiation of new pancreas β-cells leading
to increase of β-cell mass [2]. The major form of circulating human
GLP-1 is a C-terminal amidated peptide of 30 amino acid residues
indicated as GLP-1-(7-36)-amide, while a minor C-terminally glycine
extended form of 31 amino acid residues, termed GLP-1(7-37), is also
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detectable in blood. Both peptides exhibit the same biological activi-
ties, are equipotent and exert their effects by binding and activating
a speciﬁc receptor, named GLP-1 receptor and structurally related to
G-protein coupled receptor class 2 family, which is predominantly
coupled to stimulation of adenylyl cyclase activity [3]. GLP-1 recep-
tors are expressed in the β-cell of the islets of Langerhans, as well as
in gastrointestinal tract and in other tissues including heart, kidney,
lung and brain as well as vascular endothelium [4,5].
The insulinotropic action of GLP-1 peptides, that is the stimula-
tion of insulin secretion occurring when plasma glucose levels are
above the normal physiological value, makes these compounds po-
tential candidates for the treatment of type 2 diabetes. However, the
therapeutic use of GLP-1 peptides is limited by a very short plasma
half-life (for exampleGLP-1-(7-36)-amidehas a t1/2 <1.5minafter in-
travenous administration)mainly due to rapid degradation by plasma
dipeptidyl peptidase IV (DPP-IV) or CD26, a serine-type protease that
cleaves N-terminal dipeptides frompolypeptide chains after a proline
or alanine residue. The biological activity of naturally circulating GLP-
1 peptides is in fact modulated by the N-terminal DPP-IV-mediated
2211-2863/$ - see front matter c© 2012 Elsevier B.V. All rights reserved.
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cleavage at the alanine-2 residue to give the inactive metabolite des-
His–Ala-GLP-1-(7-36)-amide peptide.
Examples of more stable GLP-1 analogues include exendin-3 and
exendin-4, two 39-amino acid peptides originally isolated from the
venom of the Gila monster lizard Heloderma suspectum, which share
approximately 50% sequence identitywithGLP-1 itself and are indeed
agonists at GLP-1 receptors. A synthetic preparation of exendin-4 (ex-
enatide) has been approved in both USA and Europe as adjunctive
therapy to for the treatment of type 2 diabetes based on two daily
subcutaneous injections [6]. Exenatide, which differs from GLP-1 in
N-terminal position 2, is DPP-IV resistant and is therefore essentially
eliminated by glomerular ﬁltration. However, when injected intra-
venously, it displays a plasma half-life of about 30min.
The rapid inactivation and/or the clearance of GLP-1 peptides and
analogues raises the need of developing degradation-resistant GLP-1
receptor agonists capable of exhibiting prolonged duration of action
with respect to natural GLP-1 peptides after in vivo administration.
In the presentworkwe generated long-lasting insulinotropic pep-
tides through the conjugation of GLP-1 peptides and analogues to
polyethylene glycol (PEG) by enzymatic site-speciﬁc transglutamina-
tion reaction. Our results indicate that these compounds could ﬁnd
therapeutical applications in type 2 diabetes in combination with
suitable pharmaceutical formulations and/or slow release delivery
systems.
2. Materials
GLP-1-(7-36)-amide and GLP-1-(7-36)-amide mutants, prepared
according to the ﬂuorenylmethyl chloroformate chemistry and with
a purity > 90%, were custom synthetized by Pepscan (Lelystad,
Netherlands). Linear methoxy-polyethylene glycol-amine MW 5,000
and 20,000Da were purchased from IRIS Biotech (Marktred-
witz,Germany). Branched methoxy-polyethylene glycol-amine MW
50,000Da was obtained by NOF Corporation (Tokyo, Japan).
Dipeptidyl peptidase IV from porcine kidney (10U/mg) and exe-
natide were purchased from Sigma-Aldrich (St. Louis, MO, USA).
[α-32P]ATP (30–40Ci/mmol) and [2,8-3H]cyclic AMP (25Ci/
mmol) were obtained from Perkin–Elmer (Boston, MA, USA).
Unless otherwise speciﬁed, all other chemicals and reagents were
of analytical grade from Sigma-Aldrich and Fluka (Milan, Italy).
Macrocap SP chromatographic resin was from GE Healthcare (Up-
psala, Sweden).
3. Methods
3.1. Analytical assays
Approximately 3μg of non-reduced sample was separated by
SDS-PAGE in 15% polyacrylamide with Tris–glycine buffer [7]. Re-
solved protein bands were ﬁxed with glutaraldheyde and detected
by Coomassie Blue staining. Biorad protein markers with mass range
from 6.6 to 203.3 kDa were used as molecular weight reference.
RP-HPLC analysis of pegylated GLP-1-peptides was performed on
a C18 Supelco Discovery Bio Wide Pore column, 4.6 × 250mm, 5μm
particle size, (Bellefonte, PA, USA) at +45 ◦C and UV detection at
215nm; elutions were carried out at 0.75ml/min starting from the
mobile phases A (0.1% v/v triﬂuoroacetic acid in water) and B (0.1% v/
v triﬂuoroacetic acid in acetonitrile) with the following gradient: 15%
B for 2min; 15–34% B from 2 to 10min; 34–56% B from 10 to 20min
and 56–90% B from 20 to 27min; the columnwas ﬁnally washedwith
90% B for 5min.
Transglutaminase enzymatic activity was measured at 37 ◦C ac-
cording to a colorimetric method based on the chromogenic hydrox-
amate procedure using N-α-carbobenzoxy-l-glutaminyl-glycine as
substrate [8]. The calibration curve was prepared using l-glutamic
acid- γ-monohydroxamate and one unit (U) of enzyme activity was
deﬁned as the amount of enzyme that catalyzed the formation of
1μmol of l-glutamyl mono- hydroxamic acid per minute.
Transglutaminasemass determinationwasperformedbyRP-HPLC
analysis on a C4 Vydac 214TP52 column at +40 ◦C and UV detection
at 215nm; elutions were carried out at 0.2ml/min starting from the
mobile phases A (0.1% v/v triﬂuoroacetic acid in water) and B (0.1%
v/v triﬂuoroacetic acid in acetonitrile) with the following gradient:
30–59% B from 0 to 13min; 59–85% B from 13 to 20min. Being not
available a certiﬁed transglutaminase reference standard, transglu-
taminasewasquantiﬁedbypeak areas comparisonof standardbovine
albumin (BSA) preparations separated in the same conditions.
3.2. Enzymatic pegylation
3.2.1. Puriﬁcation of microbial transglutaminase
Microbial transglutaminase (EC. 2.3.2.13) from Streptoverticillium
mobaraensis (Activa WM, 81–135U/g) was obtained from Ajinomoto
(Tokyo, Japan) and puriﬁed by cation exchange chromatography.
Brieﬂy, a ﬁltered enzyme solution in 50mM sodium acetate–50mM
sodium chloride buffer (pH 5.5) was loaded on Macrocap SP chro-
matography column equilibrated with the same buffer and eluted
with 50mM sodium acetate–50mM sodium chloride buffer (pH 5.8).
The transglutaminase pooled fractions displayed a protein concentra-
tion of 0.368mg/ml and a speciﬁc activity of 26.7U/mg determined
by combining RP-HPLCmass determination and colorimetric assay of
enzymatic activity.
3.2.2. Pegylation reactions
GLP-1-(7-36)-amide dissolved in 20mM potassium dihydrogen
phosphate buffer (pH 7.4) at 0.5mg peptide/ml was mixed with lin-
ear monomethoxy-polyethylene glycol-amine (mPEG-NH2) of 5 or
20kDa or with branched 50kDa mPEG-NH2 to achieve a 20:1 mPEG-
NH2:GLP-1 molar ratio and with 0.25U/ml of partially puriﬁed mi-
crobial tranglutaminase. The resulting solutionwasmaintainedunder
mild agitation for 16h at room temperature to obtain GLP-1(7-36)-
amide monopegylated at glutamine 23.
The double mutant GLP-1-(7-36)-(Q23N–A30Q)-amide was re-
acted in the same conditions with linear 20 kDa mPEG-NH2 to obtain
the corresponding monopegylated derivative at glutamine 30.
The double mutant GLP-1-(7-36)-(T11Q–Q23N)-amide at a con-
centration of 0.5mg/ml in 20mM phosphate buffer pH 7.4 was re-
acted for 16h at room temperaturewith linear 5 kDamPEG-NH2 (40:1
PEG:GLP-1 molar ratio) and with 0.25U/ml of partially puriﬁed mi-
crobial transglutaminase to obtain the correspondingmonopegylated
derivative at glutamine 11.
All monopegylated GLP-1-(7-36)-amide derivatives were puriﬁed
by cation exchange chromatography after dilution of reaction mix-
tures with 20mM sodium acetate buffer (pH 4). The solutions were
loaded on a Macrocap SP chromatography column and eluted with
10 column volumes of a NaCl linear gradient from 0 to 500mM. The
fractions containing the mono-pegylated GLP-1-(7-36) amides were
concentrated by ultraﬁltration and analyzed by RP-HPLC and SDS-
PAGE.
3.3. In vitro stability of pegylated GLP-1(7-36)-amides towards DPP-IV
digestion
GLP-1-(7-36)-amide and puriﬁed mono-pegylated GLP-1-(7-36)-
amide-Q23-PEG 5kDa, GLP-1(7-36)-amide-Q23-PEG 20kDa, GLP-
1-(7-36)-amide-Q23-branched PEG 50kDa, GLP-1-(7-36)-(Q23N–
A30Q)-amide-Q30-PEG 20kDa and GLP-1(7-36)-(A11Q–Q23N)-
amide-Q11-PEG 5kDa were dissolved in phosphate buffered saline
(PBS) at a concentration of 0.1mg/ml (calculated as peptide content)
and were incubated at 37 ◦C with porcine DPP-IV (0.05U/ml of pep-
tide solution). At different incubation times, 50μl was removed from
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the reaction mixtures, and treated with 2.5μl of 10% (v/v) triﬂuo-
roacetic acid to block the enzymatic reaction. The extent of degrada-
tion was evaluated by the increase of N-terminal dipeptide His–Ala
measured by RP-HPLC on a C18 Supelco Discovery BioWide Pore col-
umn (4.6mm × 250mm, 5μm particle size) at room temperature
and UV detection at 215nm. Elutions were carried out at 0.75ml/min
starting from the mobile phases A (0.1% v/v triﬂuoroacetic acid in
water) and B (0.1% v/v triﬂuoroacetic acid in acetonitrile) with the
following gradient: 100% A for 6min; from 0% to 36% B from 6 to
15min; from 36% to 55% B from 15 to 31min and from 55% to 95%
B from 31 to 32min; the column was ﬁnally washed with 95% B for
5min.
3.4. Determination of in vitro biological activity of GLP-1(7-36)-amide
and its pegylated derivatives.
In vitro biological studies were performed on cell line RIN-m5F
derived from a radiation-induced transplantable rat insulinoma, that
not only expresses glucagon-like peptide-1 receptors in a sufﬁcient
number but also serves as a model cell line for the beta-cells [9].
3.4.1. Cell membrane preparation
Rat RIN-m5F insulinoma cells were from American Type Culture
Collection (Manassas, VA, USA). Cells were cultured in RPMI 1640
medium supplemented with 11mM glucose, 100 IU/ml penicillin,
100μg/ml streptomycin from Invitrogen (Carlsbad, CA, USA), 9mM
NaHCO3, 2mM CH3COCOONa and 10mMHEPES and 10% (v/v) foetal
calf serum (FCS) (Euroclone, Milano, Italy). Cells were maintained in
sterile 75 cm2 Corning tissue culture ﬂasks (NewYork, NY, USA) at
37 ◦C in a humidiﬁed atmosphere of 5% CO2/95% air using a Her-
aeus HERA cell 150 incubator (Hanau, Germany). Cells were grown
in 100mm plastic Petri dishes to ∼80–90% conﬂuency, the culture
mediumwas removed and the cells were washedwith ice-cold phos-
phate buffered saline (pH 7.4). Thereafter, the cells were scraped into
an ice-cold buffer containing 10mM HEPES/NaOH (pH 7.4), 1mM
EGTA and 1mM MgCl2 and lysed with a Dounce tissue grinder. The
cell lysate was centrifuged at 1000 g for 5min at 4 ◦C to remove
unbroken cells and nuclei. The supernatant was collected and cen-
trifuged at 32,000 g for 20min at 4 ◦C. The pellet was resuspended in
the homogenization buffer at a protein concentration of 2.0–2.5mg/
ml measured with the method of [10], using BSA as a standard. The
membrane preparations were either used immediately or stored at
−80 ◦C.
3.4.2. Adenylyl cyclase assay
The adenylyl cyclase activity of RINm5F cell membranes was
assayed in a reaction mixture (ﬁnal volume 100μl) containing
50mM HEPES/NaOH (pH 7.4), 2.3mM MgCl2, 0.3mM EGTA, 0.2mM
[α-32P]ATP (50 cpm/pmol), 0.5mM [3H]cyclic AMP (80 cpm/nmol),
1mM 3-isobutyl-1-methylxanthine, 5mM phosphocreatine, 50U/ml
of creatine phosphokinase, 10μM GTP, 50μg of BSA, 10μg of baci-
tracin and 10 kallikrein inhibitor units of aprotinin. Preliminary ex-
periments indicated that the stimulation of adenylyl cyclase activity
by GLP-1 (7-36)-amide was maximal at 10μMGTP. Peptide dilutions
were freshly prepared in 0.1% BSA just before the experiments, con-
stantly kept on ice and used only once. The reaction was started by
the addition of the tissue preparation (30–35μg of protein) and was
carried out at 30 ◦C for 10min. The reaction was stopped by the ad-
dition of 200μl of a solution containing 2% (w/v) SDS, 45mM ATP,
1.3mM cyclic AMP (pH 7.5). Cyclic AMP was isolated by sequential
chromatography on Dowex and alumina columns as described [11].
The recovery of [32P]cyclic AMP from each sample was calculated on
the basis of the recovery of [3H]cyclic AMP. Three separatemembrane
preparations were used. Assays were carried out in duplicate.
3.4.3. In vitro insulinotropic action
The insulinotropic activity of GLP-1 amide and its derivates was
evaluated by static incubation of RIN-m5F cells [12,13]. Cells were
seeded in 12-multiwell plates at a density of 3 × 105 cells/well, and
grown to 60–70% conﬂuency. On the third day the growth medium
was gently removed and replaced 24h before the trial.
Acute tests for insulin releasewere preceded by 2hpre-incubation
at 37 ◦C/5% CO2 in fresh RPMI 1640.
Test incubation was performed in the presence of 2mM glucose
and GLP-1-(7-36)-amide or its derivatives dissolved in RPMI 1640
without FCS at the ﬁnal concentrations ranging from 10−12 to 10−6M.
After 30min incubation the supernatant of each well was collected
and centrifuged at 1000 g in a Eppendorf centrifuge equipped with
F45-24-11 rotor for 4min at 10 ◦C. The amount of insulin content was
detected forthwith by using a rat insulin ELISA kit from Mercodia AB
(Uppsala, Sweden).
3.5. In vivo biological activity of GLP-1(7-36)-amide and its pegylated
derivatives.
All animal experiments were performed in accordance with the
provisions of the European Economic Community Council Directive
86/209 concerning the protection of animals used for experimental
and other scientiﬁc purposes, recognized and adopted by the Italian
Government with the approval decree D.M. no. 230/95-B.
3.5.1.Glucose stabilizing effect in diabetic mice
The in vivo glucose-stabilizing effect of GLP-1(7-36)-amide and
its pegylated derivatives was studied in 7- to 11-week-old diabetic
db/db mice obtained from Charles River (Calco, Italy). The mice were
distributed in three groups of seven animals each. Animalswere food-
deprived for 18h before and 3h after oral administration of a glucose
solution (1.5 g/kg body weight). Thirty minutes before glucose ad-
ministration, animals were treated subcutaneously with a solution
containing either GLP-1-(7-36)-amide-Q23-PEG 5kDa (40μg/ml) or
GLP-1-(7-36)-amide-Q23-PEG 20kDa (40μg/ml) or saline control so-
lution in a volume of 2.5ml/kg body weight to give a ﬁnal dosage
of 100μg/kg. Blood samples were collected from the tail vein of con-
sciousmiceandglucose concentrationwasmeasuredbyaGluco tester
Ascensia Elite fromBayer (Milano, Italy) before foodwithdrawing, im-
mediately prior to injections and 15, 30, 60, 120, 180, 240, 300, 1440,
1500 and 1620min post injection.
3.5.2. Pharmacokinetic studies
Pharmacokinetic studies were performed in two groups of four
adult Sprague-Dawley male rats weighing about 400 g obtained from
Charles River (Calco, Italy). The animals were treated by subcuta-
neous injection of 1mg/kg of GLP-1-(7-36)-amide-Q23-PEG5kDa and
GLP-1-(7-36)-amide-Q23-PEG 20kDa dissolved at a concentration of
0.5mg/ml in 20mM acetate–0.14M NaCl buffer (pH 4.0). Blood sam-
ples (200μl) were collected from tail vein at time 0 and 3, 6, 9, 24, 32,
48, 72 and 96h after products administration into heparinized tubes
and plasma was separated by centrifugation. Plasma GLP-1-(7-36)-
amide concentration was determined by an ELISAmethod performed
in 96-well polystyrenemicrotiter plates coated overnight at 4 ◦Cwith
100μl/well of mouse monoclonal antibody speciﬁc for the amidated
C terminus of GLP-1(7-36)-amide obtained from AntibodyShop (Gen-
tofte, Denmark). The following day the plate was washed once with
washing solution (PBS containing 0.1% v/v Tween 20) and blocked by
incubation for 1h with 200μl/well saturating solution (PBS contain-
ing 5% w/v BSA and 0.1% v/v Tween 20). Wells were then washed
four times, incubated for 1h with 100μl/well of standard and plasma
samples and washed four times. Hundred microliter of biotinylated
mouse monoclonal antibody speciﬁc for mid-molecular epitope of
GLP-1 (AntibodyShop) was added to each well. After 1 h of incuba-
tion, the plate was washed four times, incubated for another hour
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with 100μl/well Streptavidin-Horseradish Peroxidase Conjugate ob-
tained from Vector (Burlingame, CA, USA) and washed ﬁve times.
Finally, the plate was developed by incubation for 10min in the dark
with 100μl/well of TMB peroxidase substrate from Sigma and the
reaction was stopped by the addition of 100μl 1N H2SO4 per well.
Absorbances weremeasured at 450nm on a Bioradmicroplate reader
(Milan, Italy).
3.6. Statistical analysis
Results are reported as mean± SEM. Statistical analysis of the dif-
ference between means was performed by Student’s t test.
Concentration–response curves were analyzed by using a non-
linear curve ﬁtting computer program (GraphPad Prism, San Diego,
CA, USA), which yielded EC50 (concentration producing half-maximal
response) and Emax (maximal effect) values. The relative potency was
calculated according to the formula: 1/( EC50d/EC50r), in which EC50d
and EC50r are the EC50 values of the GLP-1 analog and GLP-1(7-36)-
amide, respectively. The relative efﬁcacy was calculated as percent of
the GLP-1(7-36)-amide Emax value.
The pharmacokinetics parameters were estimated using a non-
compartmentalmodel. The half-life ( t1/2) was calculated on the elim-
ination phase of the log transformed pK curve. The maximal concen-
tration ( Cmax) and time of maximal concentration ( Tmax) are the ex-
perimental data point corresponding to the maximum value of GLP-1
plasma concentration. The area under the curve (AUC) was calculated
by using the linear trapezoidal rule.
4. Results
4.1. Pegylation of GLP-1-(7-36)- amide with bacterial
transglutaminase
The single glutamine residue naturally present in position
23 of GLP-1(7-36)-amide easily reacts with linear 5 kDa and
20kDa alkylamino-monometoxy-PEG and a catalytic amount of
bacterial transglutaminase to give the GLP-1(7-36)-amide-Q23-
monopegylated derivative with yields of about 60%. However, the
sameenzymatic pegylation either does not occur or occurswith lower
yields when a single glutamine residue substituted a native residue
in other positions of the peptidic chain of GLP-1(7-36)- Q23N-amide
mutant, as shown in Table 1.
Monopegylated derivatives of natural GLP-1(7-36)-amide as well
as of GLP-1(7-36)-Q23N-amide mutants were puriﬁed by cation-
exchange chromatographywith yields around 80% to obtain homoge-
nous products as demonstrated by analytical RP-HPLC (Fig. 1). As
expected [14], the pegylation increased the apparent size of the con-
jugated peptides; for example, GLP-1(7-36)-amide-Q23-PEG 20kDa,
whichhas a calculatedmolecularweight of around23.3 kDa,migrated
in SDS-PAGE with an apparent molecular mass of 44–46kDa (Fig. 2).
4.2. Stability towards DPP-IV digestion and biological activity in vitro
GLP-1-(7-36)-amide, its mutants and the derivatives mono-
conjugated with 5, 20 or 50kDa PEG on Gln11, Gln23 and Gln30
were subjected to in vitro proteolysis by incubation with porcine
DPP-IV. The results demonstrated a high degradation rate for both na-
tive GLP-1-(7-36)-amide and its Q23N–A30Q double mutant, which
showed 50% hydrolysis of N-terminal dipeptide after a few minutes
and about 30min respectively. Conversely, GLP-1-(7-36)-amide-Q23-
PEG 20kDa and GLP-1-(7-36)-amide-Q23-PEG 50kDa as well as GLP-
1-(7-36)-(Q23N–A30Q)-amide-Q30-PEG 20kDa, exhibited a similar
slower degradation rate reaching about 50% hydrolysis after 8h incu-
bation. GLP-1-(7-36)-amide-Q23-PEG 5kDa showed a lower stability,
reaching 50% degradation after about 4h incubation, most likely due
to a minor shielding effect of the shorter PEG chain. However, both
Fig. 1. RP-HPLC analysis of puriﬁed GLP-1-(7-36)-amide-Q23-PEG 20kDa performed
on a C18 Supelco Discovery Bio Wide Pore column (4.6 × 250mm) at 45 ◦C and UV
detection at 215nm. Gradient elution was carried out at 0.75ml/min starting from the
mobile phases A (0.1% v/v triﬂuoroacetic acid in water) and B (0.1% v/v triﬂuoroacetic
acid in acetonitrile).
Fig. 2. SDS-PAGE of GLP-1-(7-36)-amide-Q23-PEG 20kDa and GLP-1-(7-36)-amide-
Q23-PEG 5kDa carried out on 15% running gel and Coomassie Blue stained after glu-
taraldehyde ﬁxation. Lane 1: standard protein markers; lane 2: GLP-1-(7-36)-amide-
Q23-PEG 20kDa; lane 3: GLP-1-(7-36)-amide-Q23-PEG 5kDa.
PEG chain length and conjugation site were important determinants
of proteolytic resistance, as demonstrated by the high stability of GLP-
1-(7-36)-(T11Q–Q23N)-amide-Q11-PEG 5kDa (15% degradation after
8h incubation), where the 5 kDa PEG chain is attached to a site closer
to the N-terminus, which is cleaved by DPP-IV (Fig. 3).
The ability of the pegylated GLP-1 derivatives to activate the GLP-
1 receptor was evaluated by measuring the stimulation of adenylyl
cyclase in RIN-mf5 cell membranes. GLP-1-(7-36)- amide and the
GLP-1mimetic peptide exenatide stimulated cyclic AMP formation in
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Table 1
Summary of enzymatic pegylations of GLP-1-(7 - 36)-amide and of its Q23N mutants, performed in phosphate buffer pH 7.4 for 16h
at room temperature.
Monopegylated GLP-1-(7 - 36)-amide derivatives
Peptide/mPEG-NH2
(Molar ratio)
MTGase
(unit/ml) Pegylation yields (%)
GLP-1-(7 - 36)-amide-Q23-PEG 5kDa 1:20 0.25 60
GLP-1-(7 - 36)-amide-Q23-PEG 20kDa 1:20 0.25 60
GLP-1-(7 - 36)-amide-Q23-PEG 50kDa* 1:20 0.25 25
GLP-1-(7 - 36)-(T11Q – Q23N)-amide-Q11-PEG 5kDa 1:40 0.25 40
GLP-1-(7 - 36)-(Q23N – A30Q)-amide-Q30-PEG 20kDa 1:20 0.25 60
GLP-1-(7 - 36)-(A8Q – Q23N)-amide-Q8-PEG 20kDa 1:20 0.25 No pegylation
GLP-1-(7 - 36)-(S17Q – Q23N)-amide-Q17-PEG 20kDa 1:20 0.25 No pegylation
GLP-1-(7 - 36)-(S18Q – Q23N)-amide-Q18PEG 20kDa 1:20 0.25 No pegylation
∗ Reaction performed with branched 50kDa PEG-NH2.
Table 2
Potencies and relative efﬁcacies of GLP-1-(7 - 36)-amide, exenatide, GLP-1 mutants and pegylated GLP-1 peptides in stimulating
adenylyl cyclase activity and insulin production in RINm5F cells. Values are the mean ± SEM of three experiments.
Samples
In vitro cAMP stimulation in plasma
membranes of rat β-cell line RIN-m5F
In vitro insulin secretion in rat β-cell
line RIN-m5F
EC50 (nM)
Relative
potency
Relative
efﬁcacy EC50 (nM)
Relative
potency
Relative
efﬁcacy
GLP-1(7 - 36)amide 0.43 ± 0.14 1 100 0.6 ± 0.2 1 100
Exenatide 0.52 ± 0.10 0.827 100 0.3 ± 0.1 2 92
GLP-1 -(7- 36)-(Q23N – A30Q)- amide 1.4 ± 0.3* 0.42 84.5
GLP-1-(7 - 36)- (T11Q – Q23N)-amide 29.9 ± 1.0* 0.014 80 28.8 ± 0.7* 0.02 100
GLP-1-(7 - 36)-amide-Q23-PEG 5kDa 9.3 ± 0.03* 0.046 100 2.7 ± 0.7* 0.22 98
GLP-1-(7 - 36)-amide-Q23-PEG 20kDa 27.0 ± 0.5* 0.016 100 34.4 ± 0.8* 0.017 80
GLP-1-(7 - 36)-amide-Q23-PEG 50kDa 1870 ± 1.0* 0.0003 94.7
GLP-1-(7 - 36)-amide-Q11-PEG 5kDa 153 ± 3* 0.0028 83 106.3 ± 0.5* 0.005 93
GLP-1-(7 - 36)-amide-Q30-PEG 20kDa 35 ± 3.0* 0.017 95
∗ p < 0.05 by Student’s t test.
Fig. 3. In vitro enzymatic degradation of GLP-1-(7-36) amide (x), GLP-1-(7-36)-amide-
Q23-PEG 20KDa (◦), GLP-1-(7-36)-(Q23N/A30Q)-amide-Q30-PEG 20KDa (Δ), GLP-1-
(7- 36)-(Q23N–A30Q)-amide (), GLP-1-(7-36)-amide-Q23-PEG 5KDa (), GLP-1-(7-
36)-amide-Q23-PEG50KDa (), GLP-1-(7-36)-(T11Q–Q23N)-amide-Q11-PEG5KDa (+),
GLP-1-(7-36)-(T11Q–Q23N)-amide (•), towards porcine dipeptidyldipeptidase IV after
8h incubation at 37 ◦C. Time course cleavage of N-terminal dipeptide Hys–Ala was
measured by RP-HPLC carried out on a C18 Supelco Discovery Bio Wide Pore column
(4.6mm × 250mm), at room temperature and UV detection at 215nm, by gradient
elutions at a ﬂow rate of 0.75ml/min starting from the mobile phases A (0.1% v/v
triﬂuoroacetic acid in water) and B (0.1% v/v triﬂuoroacetic acid in acetonitrile).
a concentration-dependent manner with Emax values corresponding
to 360 ± 22 and 358 ± 26% increase of basal value ( p < 0.001, n
= 4) and EC50 values of 0.43 and 0.52nM, respectively (Table 2). All
the pegylated derivatives displayed Emax values equal to that of GLP-
1-(7-36)-amide, conversely, important differences were observed in
the EC50 values, as pegylation signiﬁcantly reduced the potency in
stimulatingGLP-1 receptor signaling. It is noteworthy that the relative
potency of GLP-1-(7-36)-amide pegylated on Gln23 with 5 kDa PEG
was higher than the corresponding derivative pegylated with 20kDa
PEG, indicating a lower impact of the shorter PEG chain on the agonist
activity.
Additional experimentswere conducted to characterize the ability
of GLP-1-(7-36)-amide, GLP-1(7-36)-amide mutants and the corre-
sponding pegylated derivatives to induce insulin secretion from RIN-
mf5 cells in the presence of 2mM glucose (Table 2). All peptides and
pegylated derivatives stimulated insulin release in a concentration-
dependent manner within the range of 10−12–10−6M. As observed in
the adenylyl cyclase assay, themajor differenceswere observed in the
EC50 values, with a loss of potency occurring for GLP-1 mutants and
pegylated derivatives in comparison with native GLP-1(7-36)-amide.
4.3. In vivo activity of pegylated GLP-1-(7-36)-amide derivatives
Time-course of glucose stabilizing capabilities of GLP-1-(7-36)-
amide, GLP-1-(7-36)-amide-Q23-PEG 5kDa andGLP-1-(7-36)-amide-
Q23-PEG-20 kDa were assessed in diabetic mice challenged with an
oral glucose load administered 30min after a subcutaneous injection
of 100μg/kg of pegylated GLP-1 derivatives or saline. As shown in Fig.
4, the glucose-lowering effect ofGLP-1-(7-36)-amide-Q23-PEG20kDa
wasmaintained for about 8hwhile the effect of GLP-1-(7-36)-amide-
Q23-PEG 5kDa lasted not more than 3.5 h.
4.4. Pharmacokinetic properties
The pharmacokinetic proﬁles of GLP-1-(7-36)-amide-Q23-PEG
5kDa and GLP-1-(7-36)-amide-Q23-PEG 20kDa administered by sub-
cutaneous injections of 1mg/kg were studied in adult rats (Fig.
5). GLP-1-(7-36)-amide-Q23-PEG5kDaandGLP-1-(7-36)-amide-Q23-
PEG 20kDa plasma concentrations peaked respectively at 3 and 9h,
with Cmax values of 160 and 640ng/ml. GLP-1-(7-36)-amide-Q
23-
PEG 5kDa disappeared from plasma with a t 1
2
value of 1.7 h, while
the circulating concentration of GLP-1-(7-36)-amide-Q23-PEG 20kDa
decreased at a slower rate with a t 1
2
value of 17.1 h and after 96h
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Table 3
Mainpharmacokinetic parameters calculated after subcutaneous administration ofGLP-1-(7 - 36)-amide-Q23-PEG
5kDa and GLP-1-(7 - 36)-amide-Q23-PEG 20kDa.
Sample tmax (h) Cmax (ng/ml) AUC* (ng/ml×h) t1/2 (h)
GLP1-(7 - 36)-amide-Q23-PEG 20kDa 9 684.4 16,799.8 12.1
GLP1-(7 - 36)-amide-Q23-PEG 5kDa 3 160.4 1408.3 1.7
∗ AUC96h.
Fig. 4. Blood glucose levels in overnight fasted db/db diabetic mice during an oral
glucose tolerance test (1.5g/Kg) performed 30min after a s.c. injection of vehicle (x) or
of 100μg/kg GLP-1-(7-36)-amide-Q23-PEG 5kDa (Δ) and GLP-1-(7-36)-amide-Q23-PEG
20kDa (). * p < 0.05 by Student’s test
Fig. 5. Plasma concentration of GLP-1(7-36)-amide following subcutaneous admin-
istration. with 1mg/kg of GLP-1-(7-36)-amide-Q23-PEG 5kDa (•) and GLP-1-(7-36)-
amide-Q23-PEG 20kDa (◦) to rats. Blood samples for determination of GLP-1-(7- 36)-
amide concentration were collected from tail vein. Each point represents the average
of four animals.
was still around 5ng/ml. On the basis of their pharmacokinetic pro-
ﬁles, the calculated averageAUC(0→96h) for subcutaneous administra-
tionofGLP-1-(7=36)-amide-Q23-PEG5kDaandGLP-1-(7-36)-amide-
Q23-PEG 20kDa was respectively 1408 and 16,800ng/ml × h (Table
3).
The signiﬁcant contribution of 20 kDa pegylation to the increase
of circulating half-life of GLP-1 is clearly demonstrated by literature
data of GLP-1-(7-36)-amide administered subcutaneously to rats dis-
playing half-lives between 90 and 216min [15].
5. Discussion
In this paper, we report for the ﬁrst time the enzymatic pegylation
of GLP-1 peptides as an approach to obtainmodiﬁed incretinmimetic
peptides displaying maintenance of therapeutically useful biological
activity, resistance to endogenous peptidase degradation and longer
circulating half-life.
It is well-known that the conjugation of peptides or proteins to
linear or branched high molecular weight PEG modiﬁes the physico-
chemical properties of the conjugated complexes maintaining, to-
tally or in part, the biological function of the original non-conjugated
molecule, such as the capability of receptor recognition and activa-
tion. Concomitantly, the conjugated PEG chain may hamper physical
contacts between the protein and both speciﬁc and non-speciﬁc pro-
teolytic enzymes, thus preventing or reducing the enzymatic prote-
olysis [16].
Pegylated therapeutic proteins, as any other drug, should ideally
be homogeneous products with well deﬁned structural and func-
tional characteristics. However, conventional chemical pegylation of
proteins is based on non-speciﬁc reactionswith nucleophilic residues
(most commonly the ε-amino group of surface lysine residues or the
side-chain carboxylic groups) and frequently produces different ex-
tent of conjugation and/or mixtures of pegylated positional isomers.
Each of these isomers could display variations in biological properties
relevant to clinical applications, including pharmacological activity
and side-effects.
It has been reported that polypeptidic chains can be pegylated
by exploiting the preferential reactivity, at acidic pH, of the alpha-
amino group of N-terminal residue with aldehyde-functionalized
monometoxy-PEG chains followed by reductive alkylation [17]. Un-
fortunately, the N-terminal selective chemical pegylation of GLP-1
peptides results in a monoconjugated derivative with negligible in
vivo activity due to the fact that the N-terminal histidine residue is
crucial for effective receptor recognition and maintenance of biolog-
ical action [18,19].
The selective chemical pegylation of one of the two lysine residues
of GLP-1-peptides to give biologically active monopegylated deriva-
tives either on Lys26 or on Lys34 residue was only possible through a
low-yield, complex and multi-step method involving chemical pro-
tection of lysine ε-amino groups, chromatographic separation of Lys26
and Lys34 protectedGLP-1 isomers, conventional independent chemi-
cal pegylation of each isomer followedby removal of protecting group
from the non-reacted lysine residue [19].
In addition, therapeutical administration of human peptides bear-
ing amino acid substitutions and/or additions aswell as of peptides of
non-human origin, such as exenatide, may induce undesired immune
response that may decrease the drug efﬁcacy or cause adverse events
in patients. Indeed, clinical studies have shown that 40–50% of pa-
tients treated with exenatide for 30 weeks developed anti-exenatide
antibodies, which, at least in some cases, impaired treatment efﬁcacy
[20].
To overcome these limitations, we developed mono-pegylated
derivatives of GLP-1-(7-36)-amide and mutants by using the transg-
lutaminase of Streptoverticillium mobaraensis, a monomeric enzyme
with a molecular mass of about 38kDa and a Ca2+ independent cat-
alytic activity.This enzyme is able to catalyze an acyl transfer reac-
tion between a γ-carboxyamido group of peptide-bound glutamine
residues and monomethoxy-PEG chains functionalized with primary
alkylamines [21].
In this work we exploited this reaction to pegylate the single glu-
tamine residue naturally present on the incretin mimetic peptide
GLP-1-(7-36)-amide or the single glutamine residue introduced into
the GLP-1-(7-36)-(Q23N)-amide mutants in substitution of other na-
tive residues. Although no speciﬁc consensus site has been identiﬁed
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around the glutamine residues modiﬁed by bacterial transglutami-
nase catalyzed reaction, it is commonly believed that the enzyme is
able to recognize as substrate glutamine residues located on solvent
accessible, ﬂexible and locally unfolded region of the protein chain
encompassing the glutamine residues [22].
Considering the properties of bacterial tranglutaminase and the
fact that GLP-1-(7-36)-amide has no deﬁned structure in aqueous
solution [23], one may expect that any single glutamine residue in-
troduced into the peptidic chain of themutant GLP-1-(7-36)-(Q23N)-
amide would provide an alternative substrate for the transglutami-
nase catalyzedmonoconjugation reactionwithmPEG-NH2. However,
when a number of Q23N-GLP-1 glutamine-containing mutants, in-
cluding derivatives with a single glutamine substitution in positions
8, 11, 17, 18 and 30 were reacted with amino functionalized mPEG in
the presence of bacterial transglutaminase it was surprisingly found
that only two mutants were substrates for transglutaminase. In fact,
with the exception of GLP-1-(7-36)-(Q23N–A30Q)-amide and GLP-1-
(7-36)-(A11Q–Q23N)-amide monopegylated on the single glutamine
residue in positions 30 and 11, respectively, the other mutants did
not give the expected monopegylated derivatives (Table 1).
These results restricted the number of potential GLP-1-(7-36)-
amide mutants as candidates for enzymatic monopegylation and this
number was further reduced by excluding the residues involved in
GLP-1-receptor binding, that is residues in positions 7, 10, 12, 13, 15,
19, 21, 29 and 32 [24,9].
On the basis of these considerations as well as of described exper-
imental results, we chose to investigate native GLP-1-(7-36)-amide
pegylated on the single Gln23 residue as potential candidate for treat-
ing type 2 diabetes. In fact, this derivative showed: (a) simple prepa-
ration with acceptable yields, (b) maintenance of sufﬁciently high
level of agonist activity at the GLP-1 receptors, (c) increased prote-
olytic stability, (d) long circulating half-life and (e) improved glucose-
stabilizing capability.
Monopegylated GLP-1-(7-36)-amide peptides are easily prepared
by an enzyme catalyzed reaction of aqueous buffer solutions of pep-
tides in the presence of 20M excess of mPEG-NH2 and of prepara-
tion of S. mobaraensis transglutaminase. The enzymatic pegylations
were carried out at room temperature and the yields were generally
not higher than 60% due to the transglutaminase which causes an
inter-molecular crosslinking of GLP-1 by formation of an isopeptide
bond involving the side chains of Gln and Lys residues, as shown
for example in Fig. 6 which refers to the preparation of GLP-1-(7-
36)-amide-Q23-PEG 20kDa. One step puriﬁcation of pegylated GLP-1
peptides was then performed by loading the reaction mixture on a
cation-exchange chromatography column and eluting with a saline
gradient. It is worth noting that the enzymatic pegylation of GLP-1-
(7-36)-amidepeptides is only catalyzedbybacterial tranglutaminases
but not by mammalian tranglutaminases. Indeed, we did not obtain
any pegylated GLP-1 peptide when the reactions were carried out
in the presence of puriﬁed guinea-pig liver transglutaminase (data
not shown), conﬁrming the broader substrate speciﬁcity of bacterial
enzyme already reported in literature [21].
The biological activities of a small peptide as the 30 residue GLP-1-
(7-36)-amide, whose molecular mass is only 3298Da, can be greatly
inﬂuenced by the chain length of conjugated PEG, as exempliﬁed by
the behavior of GLP-1-(7-36)-amide-Q23-PEG 5kDa. In the case of this
product, the conjugation of a 5 kDa PEG chain reduced the potency
in stimulating cyclic AMP formation and insulin release by 21- and
5-fold, respectively, as compared with the non-pegylated GLP-1-(7-
36)-amide, whereas it protected the peptide from in vitro proteolysis
by DPP-IV, as 50% degradation required 4h and less than 10min for
the pegylated and non-pegylated peptide, respectively. However, the
increase of hydrodinamic size conferred by a single 5 kDa chain was
not sufﬁcient to reduce the renal clearance of GLP-1-(7-36)-amide-
Q23-PEG 5kDa to a great extent, as demonstrated by the t1/2 value
of 1.7 h found in the rat pharmacokinetic study. On the other hand,
Fig. 6. RP-HPLC analysis of pegylationmixture after 16h reaction at room temperature
of GLP-1-(7-36) amide (0.5mg/ml) with mPEG-NH2 20kDa in 20mM phosphate buffer
pH 7.3 in the presence of 0.25unit/ml of bacterial transglutaminase. Reaction mixture
was applied to a C18 Supelco Discovery Bio Wide Pore column (4.6 × 250mm2) RP-
HPLC and analysis was carried out by gradient elution at +45 ◦C and UV detection at
215nm with a ﬂow rate of 0.75ml/min starting from the mobile phases A (0.1% v/v
triﬂuoroacetic acid in water) and B (0.1% v/v triﬂuoroacetic acid in acetonitrile).
the GLP-1-(7-36)-amide-Q23-PEG 20kDa, conjugated with a larger
20 kDa PEG chain, showed a signiﬁcant circulating half-life increase
with a t1/2 value of 12.1 h as well as a better resistance to in vitro
DPP-IV proteolytic degradation. It is worth noting that the mutant
GLP-1-(7-36)-(Q23N–A30Q)-amide monopegylated on Gln30 with a
PEG 20kDa gave exactly the same degradation rate and that no fur-
ther improvement of resistance to DPP-IV degradation was obtained
when GLP-1-(7-36)-amide was pegylated with a much bigger 50 kDa
branched PEG chain.
5.1. Conclusions
Finally, even if the agonist potency of GLP-1-(7-36)-amide-Q23-
PEG 20kDa was reduced by 50–60 fold with respect to the non-
pegylated GLP-1-(7-36)-amide, the combination of resistance to-
wards DDP-IV and reduced renal clearance enabled GLP-1-(7-36)-
amide-Q23-PEG 20kDa to display a glucose-stabilizing action lasting
up to 8h in diabetic mice. Although the pharmacokinetic parameters
of biodrugs derived from animals may not be predictive in humans, it
is reasonable to estimate that the therapeutic application of GLP-1-(7-
36)-amide-Q23-PEG 20kDa for the treatment of diabetes will require
more than once-a-day injections.
Studies are therefore in progress to investigate whether the incor-
poration of GLP-1-(7-36)-amide-Q23-PEG 20kDa in sustained release
formulations will be able to control hyperglycemia in type 2 diabetic
patients on the basis of once a week or twice amonth administration.
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